![Vertex pharma resized 355x200.jpg](https://www.bioindustry.org/static/uploaded/6919f381-6402-4e63-84b590134cefa15c.jpg)
Vertex Pharmaceuticals (Europe) Ltd
Drug Discovery
- Website
- http://www.vrtx.com
- Membership category
- Corporate Pharma
Level 9, Paddington Central, 2 Kingdom Street, London, W2 6BD,
Vertex Pharmaceuticals (Europe) Ltd at a glance
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved
About Vertex Pharmaceuticals (Europe) Ltd
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.
Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America.